Literature DB >> 15252854

Extensive analysis of the 7q31 region in human prostate tumors supports TES as the best candidate tumor suppressor gene.

Laurent Chêne1, Christiane Giroud, François Desgrandchamps, Laurent Boccon-Gibod, Olivier Cussenot, Philippe Berthon, Alain Latil.   

Abstract

Loss of heterozygosity (LOH) on chromosome arm 7q31 is found in many prostate tumors. Such alterations are generally associated with inactivation of tumor suppressor genes. It has been shown previously that the main region of LOH at 7q31 spans the interval between the D7S486 and D7S2460 microsatellite loci, which contains several candidate tumor suppressor genes (TSG) such as TES, CAV2, CAV1, MET, CAPZA2, ST7 and WNT2. We tested 41 human sporadic prostate tumors for 7q31 LOH by using 5 polymorphic markers overlapping the critical region and used a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assay to study the expression of the 7 candidate TSGs located in this genomic region. We found that CAV1, CAV2, MET and TES mRNA expression was lower in prostate tumors than in normal prostate tissues. Our immunohistochemical results and previously published data on the compartmental expression of these messenger RNAs in stromal and epithelial cells suggest that TES is the best candidate tumor suppressor gene at 7q31. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252854     DOI: 10.1002/ijc.20337

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  14 in total

1.  Molecular Validation of PACE4 as a Target in Prostate Cancer.

Authors:  François D'Anjou; Sophie Routhier; Jean-Pierre Perreault; Alain Latil; David Bonnel; Isabelle Fournier; Michel Salzet; Robert Day
Journal:  Transl Oncol       Date:  2011-06-01       Impact factor: 4.243

2.  Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity.

Authors:  Marcel W Coolen; Clare Stirzaker; Jenny Z Song; Aaron L Statham; Zena Kassir; Carlos S Moreno; Andrew N Young; Vijay Varma; Terence P Speed; Mark Cowley; Paul Lacaze; Warren Kaplan; Mark D Robinson; Susan J Clark
Journal:  Nat Cell Biol       Date:  2010-02-21       Impact factor: 28.824

3.  TES was epigenetically silenced and suppressed the epithelial-mesenchymal transition in breast cancer.

Authors:  Yang Yongbin; Li Jinghua; Zhao Zhanxue; Zang Aimin; Jia Youchao; Shang Yanhong; Jiao Manjing
Journal:  Tumour Biol       Date:  2014-08-15

4.  PDLIM4, an actin binding protein, suppresses prostate cancer cell growth.

Authors:  Donkena Krishna Vanaja; Michael E Grossmann; John C Cheville; Mozammel H Gazi; Aiyu Gong; Jin San Zhang; Katalin Ajtai; Thomas P Burghardt; Charles Y F Young
Journal:  Cancer Invest       Date:  2009-03       Impact factor: 2.176

5.  Extensive analysis of D7S486 in primary gastric cancer supports TESTIN as a candidate tumor suppressor gene.

Authors:  Haiqing Ma; Desheng Weng; Yibing Chen; Wei Huang; Ke Pan; Hui Wang; Jiancong Sun; Qijing Wang; Zhiwei Zhou; Huiyun Wang; Jianchuan Xia
Journal:  Mol Cancer       Date:  2010-07-13       Impact factor: 27.401

6.  Silencing of TESTIN by dense biallelic promoter methylation is the most common molecular event in childhood acute lymphoblastic leukaemia.

Authors:  Robert J Weeks; Ursula R Kees; Sarah Song; Ian M Morison
Journal:  Mol Cancer       Date:  2010-06-24       Impact factor: 27.401

Review 7.  The cellular and molecular carcinogenic effects of radon exposure: a review.

Authors:  Aaron Robertson; James Allen; Robin Laney; Alison Curnow
Journal:  Int J Mol Sci       Date:  2013-07-05       Impact factor: 5.923

8.  Chromosomal structural variations during progression of a prostate epithelial cell line to a malignant metastatic state inactivate the NF2, NIPSNAP1, UGT2B17, and LPIN2 genes.

Authors:  Ankit Malhotra; Yoshiyuki Shibata; Ira M Hall; Anindya Dutta
Journal:  Cancer Biol Ther       Date:  2013-07-26       Impact factor: 4.742

9.  TESTIN suppresses tumor growth and invasion via manipulating cell cycle progression in endometrial carcinoma.

Authors:  Zhenpeng Gu; Guofeng Ding; Kuixiang Liang; Hongtao Zhang; Guanghong Guo; Lili Zhang; Jinxiu Cui
Journal:  Med Sci Monit       Date:  2014-06-14

10.  Androgen receptor CAG repeats, non-random X chromosome inactivation, and loss of heterozygosity at Xq25 in relation to breast cancer risk.

Authors:  Hui-Tzu Chen; Yao-Chung Wu; Shou-Tung Chen; Hsien-Chang Tsai; Yi-Chih Chien
Journal:  BMC Cancer       Date:  2014-03-01       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.